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Nature of Glutamate Alterations in Schizophrenia
AMeta-analysis of ProtonMagnetic Resonance
Spectroscopy Studies
KateMerritt, MSc; Alice Egerton, PhD; Matthew J. Kempton, PhD; Matthew J. Taylor, DPhil;
Philip K. McGuire, FMedSci
IMPORTANCE Alterations in glutamatergic neurotransmissionmay be fundamental to the
pathophysiology of schizophrenia, and the glutamatergic system is a target for novel
therapeutic interventions in the disorder.
OBJECTIVE To investigate the nature of brain glutamate alterations in schizophrenia by
conducting a meta-analysis of glutamate protonmagnetic resonance (MRS) spectroscopy
studies.
DATA SOURCES TheMEDLINE database was searched for studies published from January 1,
1980, to April 1, 2015. Search terms includedmagnetic resonance spectroscopy,
schizophrenia, psychosis, clinical or genetic high risk, and schizoaffective. Inclusion criteria
were single voxel 1H-MRS studies reporting glutamate, glutamine or Glx values for a patient or
risk group in comparison to a healthy volunteer group.
STUDY SELECTION Fifty-nine studies were identified, which included 1686 patients and 1451
healthy individuals serving as controls.
DATA EXTRACTION AND SYNTHESIS A random-effects, inverse-weighted variancemodel was
used to calculate the pooled effect size. Mean values were extracted and verified
independently. Effect sizes were determined for glutamate, glutamine, and Glx in brain
regions that had been examined in at least 3 different studies. A secondary analysis grouped
studies into those examining patients at different stages of illness (high risk, first-episode
psychosis, or chronic schizophrenia). Effects of age, antipsychotic dose, and symptom
severity were determined usingmeta-regression.
RESULTS In schizophrenia, there were significant elevations in glutamate in the basal ganglia
(Hedges g = 0.63; 95% CI, 0.15-1.11), glutamine in the thalamus (g = 0.56; 95% CI, 0.02-1.09),
and Glx in the basal ganglia (g = 0.39; 95% CI, 0.09-0.70) andmedial temporal lobe
(g = 0.32; 95% CI, 0.12-0.52). No region showed a reduction in glutamate metabolites in
schizophrenia. Secondary analyses revealed that elevatedmedial frontal Glx levels were
evident in individuals at high risk for schizophrenia (g = 0.26; 95% CI, 0.05-0.46) but not in
those with first-episode psychosis or chronic schizophrenia, whereas elevated Glx in the
medial temporal lobe was seen with chronic schizophrenia (g = 0.40; 95% CI, 0.08-0.71) but
not in the high-risk or first-episode groups. Meta-regression found no association with age,
symptom severity, or antipsychotic dose.
CONCLUSIONS AND RELEVANCE Schizophrenia is associatedwith elevations in glutamatergic
metabolites across several brain regions. This finding supports the hypothesis that
schizophrenia is associated with excess glutamatergic neurotransmission in several limbic
areas and further indicates that compounds that reduce glutamatergic transmissionmay
have therapeutic potential.
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S everal lines of evidence have implicated alterations ofthe glutamatergic system in the cause of schizophre-nia. The N-methyl-D-aspartate receptor (NMDAR) hy-
pofunction model1 proposes that schizophrenia is related to
dysfunction of NMDARs on parvalbumin-containing γ-ami-
nobutyric acid–ergic interneurons, leading to excess gluta-
mate release.2 Administration of NMDAR antagonists, such
as ketamine, induce a psychotic state in healthy volunteers
and exacerbate psychotic symptoms in patients with
schizophrenia.3 More recently, an autoimmune disorder
associated with autoantibodies to the NMDARs has been
associated with psychotic symptoms, and NMDAR auto-
antibodies may be evident in a small proportion of patients
with schizophrenia.4 Several genes associated with schizo-
phrenia code for proteins involved in glutamatergic neuro-
transmission.5 The main technique for assessing central
glutamate function in man in vivo is proton magnetic reso-
nance spectroscopy (MRS).
DependingontheprotonMRSapproachandfield strength,
bothglutamateand theglutamatemetabolite, glutamine,may
be reported separately or in combination (Glx).6 Glutamater-
gicmetabolites areusuallymeasured inapredeterminedvoxel
of interest. Concentration estimates reflect both intracellular
and extracellular glutamate and glutamate involved in me-
tabolism aswell as in neurotransmission.7 Over the past 2 de-
cades, several studieshaveusedprotonMRS to investigate re-
gionalglutamateconcentrations inpatientswithschizophrenia
compared with those in healthy volunteers. However, find-
ings have not been consistent across studies, including re-
ports of elevations,8-26 nodifferences,27-51 and reductions52-63
in thepatientgroupacross avarietyofbrain regions.Thesedif-
ferencesmay relate to regional effects, protonMRSmethodo-
logic differences, stage24,57-59 or severity64 of illness, or treat-
ment effects.17,20 The first meta-analysis65 of these studies
reporteddecreases in glutamate and increases in glutamine in
themedial frontal cortex of patients comparedwith controls.
The total numberof publicationshasmore thandoubled since
the first meta-analysis, which included studies up until 2011.
Thesemore recent reports include studies on regions of inter-
est that had previously been examined too infrequently to be
included in a meta-analysis. Moreover, the field now in-
cludes substantial numbers of studies in individuals at high
risk (HR) for schizophrenia and those with first-episode psy-
chosis (FEP), in addition to studies in patients with chronic
schizophrenia, permitting separatemeta-analysesof thesedif-
ferent groups.
The primary aim of this studywas to conduct an updated
case-control meta-analysis of all published reports of re-
gional glutamatergicmeasures in those at HR for schizophre-
nia,withFEP, andwith schizophrenia. The second aimwas to
conduct case-control meta-analyses in clinical subgroups
separately (HR, FEP, and chronic schizophrenia [referred to
as schizophrenia hereinafter]). The third aim was to assess
the influences of age, symptom severity, and antipsychotic
treatment.
The first hypothesis of the studywas that, on the basis of
preclinical schizophreniamodels showing increases in gluta-
matergic transmission,66 glutamatergicmetaboliteswouldbe
increased in cases compared with controls. The second hy-
pothesis was that there would be higher glutamatergic me-
tabolite concentrations in FEP and HR individuals compared
with thosewhohad schizophrenia, in linewithprevious stud-
ies comparing patient groups.23,24,57-59 The third hypothesis
was that glutamate andglutamine levelswouldbecome lower
with antipsychotic treatment17,20,21 as well as with age in
cases relative to controls,65 but that symptom severitywould
be associated with higher glutamatergic metabolite con-
centrations.64
Methods
Study Selection
The MEDLINE database was searched to identify journal ar-
ticles published between January 1, 1980, and April 1, 2015,
using the following search terms:MRS ormagnetic resonance
spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR
or (4) ARMS or (5) ultra high risk or (6) clinical high risk or (7)
genetichigh riskor (8)prodrom*or (9) schizoaffective.All single-
voxel protonMRS studies reporting glutamate, glutamine, or
Glx values for a patient or risk group in comparison with a
healthy volunteer groupwere included in the analysis. In the
caseof longitudinal studies,17,43,52 only thevaluesgiven for the
first time pointwere included. If the same sample or partially
overlapping sampleswere included inmore than 1 report, data
from the studywith the largest sample were included (Refer-
ences 9, 10, 17, 24, 38, 43, 45, 52, 54, 62).
Meta-analysis
Meanvalues of protonMRSglutamate, glutamine, orGlx con-
centrationswere extracted byoneof us (K.M.) andverified by
another (A.E.) independently and categorized into the follow-
ing brain regions of interest: (1) medial frontal cortex, includ-
ing studies with voxels in themedial prefrontal cortex and in
the anterior cingulate cortex since these voxels often spa-
tially overlap; (2) dorsolateral prefrontal cortex (DLPFC); (3)
frontal white matter; (4) thalamus; (5) medial temporal lobe
(MTL) (including hippocampus); (6) basal ganglia (including
caudate, putamen, and globus pallidus); and (7) cerebellum.
Key Points
Question What is the nature of glutamate alterations in
schizophrenia as revealed by studies using protonmagnetic
resonance spectroscopy?
Findings This meta-analysis evaluated 59 studies reporting on
regional glutamate, glutamine, or their combined Glx signals.
There were significant elevations in glutamate in the basal ganglia,
glutamine in the thalamus, and Glx in the basal ganglia andmedial
temporal lobe but no associations with age, symptom severity, or
antipsychotic medication dose.
Meaning Schizophrenia is associated with elevations in
glutamate-relatedmetabolites across several brain regions
consistent with the hypothesis that there is excess glutamatergic
neurotransmission in this condition.
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Only analyses for which at least 3 independent data sets were
availablewere included.Whenmorethan1clinicalgroupwasre-
ported inasingle study, thevalueswere treatedas independent
data setsandthenumberofhealthyvolunteerswasadjustedby
dividing by the number of clinical groups. When data were re-
portedbilaterally,onlythoseforthelefthemispherewereincluded
because the left hemispherewas examined inmost studies.
The ability of protonMRS to resolve the overlapping reso-
nances of glutamate and glutamine increases with field
strength. Previous estimates6 of the degree of contamination
of glutamate andglutamine signals at different field strengths
using optimized sequences indicated that it would be appro-
priate to include studies reporting glutamate if the data were
acquired at field strengths of 3 T or above and studies report-
ing glutamine at 4 T or above. A secondary analysis included
data acquired at all field strengths.
TheprotonMRSmeasuresof glutamate, glutamine, orGlx
were analyzed separately, whichwas accounted for by apply-
ing a Bonferroni-corrected threshold for statistical signifi-
cance of P < .017. The effect size statistic Hedges g, which in-
corporates a correction for bias from small sample sizes, was
calculated by subtracting the mean glutamate, glutamine, or
Glx values reported in cases by themeanvalue reported in the
control group divided by the pooled SD across groups.67 If
means or SDs were not reported, authors were contacted for
this information. A Hedges g value of 0 indicates no differ-
ence between cases and controls, negative values indicate
lower glutamatergic metabolite levels in cases than controls,
andpositivevaluesdenotehigherglutamatergicmetabolite lev-
els in cases than controls.
A random-effects, inverse-weightedvariancemodel68was
used to calculate the pooled effect size since the studieswere
expected to display high heterogeneity as different correc-
tionmethodsandclinical sampleswereused. Studyeffect size
was weighted according to sample size. Heterogeneity was
measured using the I2 value, with higher percentages denot-
ing higher variation across studies in the meta-analysis. The
meta-analysis foreachbrain regionwasperformedusingmeta-
analytical equations entered intoExcel (Microsoft Corp) (http:
//www.depressiondatabase.org).Theseequationsare identical
to the METAN command in Stata (StataCorp LP), which is
commonly used in meta-analyses publications. In terms of
validation, themethod has been used in parallel with Stata in
previous meta-analyses69 and produced the same results.
Effect sizeswere initiallycalculatedforallpatientsandcon-
trols and then for each clinical group (HR, FEP, and schizo-
phrenia) separately. Separate analysis was also performed of
patient groups (FEP and schizophrenia) since most HR indi-
viduals will not develop psychosis.
Meta-regression
Toexplore the relationshipbetweenglutamate,glutamine,and
Glx effect sizes for each study and selected demographics or
clinical variables, randomeffectsmeta-regressionswere con-
ductedusing themetaregcommand inStata,version11.22009.
Thevariables investigatedwereage;PositiveandNegativeSyn-
drome Scale (PANSS)70 total; positive, negative, and general
subscale scores; chlorpromazine-equivalent dose; and dura-
tion of illness. In studies that used the Brief Psychiatric Rat-
ing Scale, the scoreswere converted to PANSS scores.71When
these measures were not reported, study authors were con-
tacted to request thedata.Publicationbiaswasexaminedusing
the Egger regression test for regions including at least 10
studies72 and meta-regressions of study effect size and year
of publication. A leave-one-out jackknife sensitivity analysis
was conducted for regionswith at least 4 studies inwhich sig-
nificant between-group differences were found.
Results
The literature search identified 59 studies,with a total of 1686
cases and 1451 controls (PRISMA flow diagram presented in
eFigure 1 in the Supplement). The sample sizes ranged from5
to 84 for cases and 4 to 81 for healthy volunteers (eTable 1 in
the Supplement). Two studies73,74 reporting multivoxel data
were excluded.
Fourteen studies (References 18, 25, 26, 29, 31, 37, 49, 51-
53, 56, 57, 62, 75) examined participants at HR for psychosis.
Eighteen studies (References9, 12, 17-19, 23, 24, 28, 30, 32, 33,
45, 48, 57-59, 63, 76) examined patients experiencing a first
episode of psychosis (FEP), all with an onset of illness within
the last 2½ years. Thirty-six studies (References 8, 10, 11, 13-
16, 20-24, 27, 31, 34-36, 38-44, 46, 47, 50, 53-55, 57-61, 77) ex-
amined patients with established (chronic) schizophrenia
(eResults in the Supplement provide detailed patient infor-
mation).
Meta-analysis
In the medial frontal cortex, there were no significant find-
ings for glutamate (HRgroup, 3; FEPgroup, 3; and schizophre-
nia group, 11), Glx (HRgroup, 8; FEPgroup, 3; and schizophre-
nia group, 13) or glutamine (HR group, 0; FEP group, 2; and
schizophrenia group, 3) (Table and eFigure 2 in the Supple-
ment). Analysis of each clinical group separately revealed
higherGlx concentrations inHR individuals (g = 0.26; 95%CI,
0.05-0.46; P = .01). There were no significant between-
group differences in glutamate or glutamine levels.
In the frontal white matter, there were no significant ef-
fects overall for glutamate (HR group, 1; FEP group, 1; schizo-
phrenia group, 1; and FEP + schizophrenia group, 1) or Glx (HR
group,0;FEPgroup,2;andschizophreniagroup,7) incasescom-
pared with controls, and only 1 study76 examined glutamine
(Table). The schizophrenia group showed elevated Glx levels
comparedwith controls (g = 0.42; 95%CI, 0.18-0.66;P = .001).
In the DLPFC, there were no significant effects for Glx in
cases (HRgroup, 2; FEP group, 2; and schizophrenia group, 8)
or in the schizophrenia group. There were insufficient data
above1.5T forglutamateandat4T forglutamine in theDLPFC.
In the basal ganglia, both glutamate (HR group, 1; FEP
group, 2; and schizophrenia group, 1; g = 0.63; 95% CI, 0.15-
1.11; P = .01) andGlx concentrations (HR group, 4; FEP group,
3; and schizophrenia group, 2; g = 0.39; 95% CI, 0.09-0.70;
P = .01) (Figure 1andFigure2)werehigher incases than incon-
trols. Subgroup analysis of Glx found elevations in the FEP
group (g = 0.66; 95%CI, 0.28-1.03;P < .001) but not in theHR
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Table. Meta-analysis Results Summary for All Patient Groups in All Brain Regions
Brain Region by
Metabolite Group Studies Cases
Healthy
Controls
Effect Size Heterogeneity
95% CI P Value I2, % P Value
Medial frontal
cortex
Glutamate All cases (3 HR, 3 FEP, 11 SZ) 17 411 381 −0.14 (−0.34 to 0.06) .17 39.7 .05
HR 3 102 80 −0.09 (−0.68 to 0.50) .77 61.3 .08
FEP (0 medicated, 3 unmedicated) 3 34 28 −0.09 (−0.46 to 0.29) .64 12.8 .32
SZ (11 medicated, 0 unmedicated) 11 242 233 −0.16 (−0.44 to 0.12) .24 18.7 .04
Glutamine All cases (0 HR, 2 FEP, 3 SZ) 5 84 78 0.19 (−0.38 to 0.76) .52 67.7 .02
SZ (3 medicated, 0 unmedicated) 3 50 50 −0.19 (−0.78 to 0.40) .53 51.7 .13
Glx All cases (8 HR, 3 FEP, 13 SZ) 24 487 440 0.12 (−0.02 to 0.27) .10 13.1 .28
HR 8 203 183 0.26 (0.05 to 0.46) .01a 0.0 .51
FEP (1 medicated, 2 unmedicated) 3 49 49 0.03 (−0.37 to 0.42) .90 0.0 .37
SZ (12 medicated, 1 unmedicated) 13 235 208 0.02 (−0.21 to 0.24) .89 20.5 .24
DLPFC
Glutamate All cases (0 HR, 0 FEP, 1 SZ) 1 NA NA NA NA NA NA
Glutamine All cases (0 HR, 0 FEP, 0 SZ) 0 NA NA NA NA NA NA
Glx All cases (2 HR, 2 FEP, 8 SZ) 12 262 184 −0.27 (−0.63 to 0.09) .15 68.6 <.001
SZ (7 medicated, 1 unmedicated) 8 172 132 −0.32 (−0.85 to 0.21) .23 77.6 <.001
Frontal WM
Glutamate All cases (1 HR, 1 FEP, 1 SZ, 1
FEP + SZ)
4 57 48 −0.18 (−0.64 to 0.28) .44 25.6 .26
Glutamine All cases (0 HR, 1 FEP, 0 SZ) 1 NA NA NA NA NA NA
Glx All cases (0 HR, 2 FEP, 7 SZ) 9 261 135 0.24 (−0.06 to 0.54) .11 46.2 .06
SZ (4 medicated, 3 unmedicated) 7 200 110 0.42 (0.18 to 0.66) .001a 0.0 .58
MTL
Glutamate All cases (3 HR, 0 FEP, 3 SZ) 6 83 91 −0.24 (−0.71 to 0.24) .33 55.3 .05
HR 3 47 49 −0.34 (−0.86 to 0.17) .19 30.7 .24
SZ (2 medicated, 1 mixed) 3 36 43 −0.08 (−1.02 to 0.86) .87 75.0 .02
Glutamine All cases (0 HR, 0 FEP, 0 SZ) 0 NA NA NA NA NA NA
Glx All cases (5 HR, 5 FEP, 8 SZ) 18 441 350 0.32 (0.12 to 0.52) .002a 42.0 .03
HR 5 112 78 0.36 (−0.14 to 0.86) .16 56.7 .06
FEP (4 medicated, 1 unmedicated) 5 132 94 0.12 (−0.16 to 0.40) .39 2.2 .39
SZ (5 medicated, 3 unmedicated) 8 197 179 0.40 (0.08 to 0.71) .01a 51.3 .04
Basal ganglia
Glutamate All cases (1 HR, 2 FEP, 1 SZ) 4 89 83 0.63 (0.15 to 1.11) .01a 57.2 .07
Glutamine All cases (0 HR, 0 FEP, 0 SZ) 0 NA NA NA NA NA NA
Glx All cases (4 HR, 3 FEP, 2 SZ) 9 216 182 0.39 (0.09 to 0.70) .01a 51.5 .04
HR 4 116 102 0.23 (−0.34 to 0.80) .43 73.7 .01
FEP (1 medicated, 2 unmedicated) 3 59 56 0.66 (0.28 to 1.03) <.001a 0.0 .99
Thalamus
Glutamate All cases (1 HR, 2 FEP, 1 SZ) 4 125 103 −0.20 (−0.47 to 0.08) .16 4.5 .37
Glutamine All cases (0 HR, 2 FEP, 1 SZ) 3 50 48 0.56 (0.02 to 1.09) .04 40.5 .19
Glx All cases (3 HR, 2 FEP, 2 SZ) 7 240 159 0.07 (−0.17 to 0.32) .56 24.1 .24
HR 3 120 101 0.16 (−0.39 to 0.71) .57 71.7 .03
Cerebellum
Glutamate All cases (1 HR, 2 FEP, 0 SZ) 3 59 58 0.38 (−0.17 to 0.93) .17 54.2 .11
Glutamine All cases (0 HR, 0 FEP, 0 SZ) 0 NA NA NA NA NA NA
Glx All cases (1 HR, 2 FEP, 0 SZ) 3 59 58 0.22 (−0.25 to 0.68) .36 37.5 .20
Abbreviations: DLPFC, dorsolateral prefrontal cortex; FEP, first-episode
psychosis; Glx, combined glutamate and glutamine signal; HR, high risk; MTL,
medial temporal lobe; NA, not applicable; SZ, chronic schizophrenia; WM, white
matter.
a Results that survivedmultiple comparisons for each region as glutamate,
glutamine, and Glx were investigated.
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group; therewere insufficient studies in patientswith schizo-
phrenia to determine the results.
In theMTL,Glxwas increased incases comparedwithcon-
trols (HR group, 5; FEP group, 5; and schizophrenia group, 8;
g = 0.32; 95%CI, 0.12-0.52;P = .002) (Figures 1 and2) but not
glutamate (HRgroup,3;FEPgroup,0;andschizophreniagroup,
3). Subgroupanalysis foundsignificantlyhigherGlxonly in the
schizophrenia group (g = 0.40; 95% CI, 0.08-0.71; P = .01)
(Figure 2). There were no between-group differences in glu-
tamate levels. The same resultswere foundafter excludingpa-
tients with 22q11 deletion.16 There were insufficient data at 4
T for glutamine.
In the thalamus, glutamine concentrationswerehigher in
cases than controls (FEP group, 2; schizophrenia group, 1;
g = 0.56; 95%CI, 0.02-1.09;P = .04) (Figure 2). Therewereno
between-group differences in glutamate (HR group, 1; FEP
group, 2; and schizophrenia group, 1) orGlx (HRgroup, 3; FEP
group, 2; and schizophrenia group, 2). No significant effects
werepresent for glutamateorGlx in thecerebellum(HRgroup,
1; FEP group, 2; and schizophrenia group, 0) (Table).
Analysis Limited to Patient Groups
When analysis was limited to patients by excluding the HR
group, no additional significant findingswere apparent in any
region (eTable2 in theSupplement).ElevatedGlx levels inMTL
(g = 0.31; 95% CI, 0.09-0.53; P = .007) and basal ganglia
(g = 0.57; 95%CI, 0.26-0.88;P < .001), aswell as elevatedglu-
tamine levels in the thalamus (g = 0.56; 95% CI, 0.02-1.10;
P = .04), remainedsignificant;however, glutamate in thebasal
ganglia (P = .08) was no longer significant.
Meta-analysis Including Studies at Low Field Strength
Meta-analyses were repeated including studies that mea-
sured glutamate or glutamine at low field strengths (<3 T for
glutamate12,23,28,32 or <4T for glutamine (References 10, 12, 13,
16, 23, 32, 35, 55, 62, 77)). Inclusion of these studies did not
change the finding of no difference in glutamate levels over-
all in themedial frontal region, althoughglutamine levelswere
significantly elevated in cases (HRgroup, 1; FEP group, 3; and
schizophrenia group, 7; g = 0.35; 95% CI, 0.02-0.67; P = .04;
I2 = 63%) and in the FEP group (g = 0.84; 95% CI, 0.38-1.30;
P < .001; I2 = 0%).
In the DLPFC, there were no significant effects for gluta-
mate (HR group, 0; FEP group, 3; and schizophrenia group, 3)
or glutamine (HRgroup,0;FEPgroup, 2; schizophrenia group,
4) in cases comparedwith controls. The schizophrenia group
showedelevatedglutamine levels in theDLPFC (g = 0.46;95%
CI, 0.06-0.86;P = .02; I2 = 25%),whichwas no longer signifi-
cant when 1 study16 in patients with a 22q11 deletion was ex-
cluded. There were no between-group differences in gluta-
mate levels.
In theMTL, glutamine levelswere increased in cases com-
pared with controls (HR group, 1; FEP group, 1; and schizo-
phreniagroup,2;g = 0.41;95%CI,0.02-0.80;P = .04; I2 = 0%).
There remainednodifferences in glutamate for cases or sepa-
rate clinical groups (HR group, 3; FEP group, 1; and schizo-
phrenia group, 4). The same results were found after exclud-
ing patients with a 22q11 deletion.16
All studies of glutamate in the frontal whitematter, basal
ganglia, thalamus, and cerebellumwere above 1.5 T. All stud-
ies of glutamine in the thalamus were at 4 T.
Figure 1. Summary Effect Sizes for Glutamatergic Differences Between Cases and Controls in Each Brain Region
Examined
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Figure 2. Study Effect Sizes in Brain Regions Showing Significant Glutamatergic Differences Between Cases
and Controls
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Heterogeneity
Significant heterogeneity was found in numerous groups for
all regions (Table), which justifies the use of a random-
effectsmodel to combine the effect sizes. Heterogeneitymay
result frommethodologic differences (eTable 3 in the Supple-
ment).Meta-regression analysis investigatedpossible sources
of heterogeneity.
Meta-regression
The clinical and demographic measures that were available
from each study for meta-regression are presented in eTable
1 in the Supplement. In all brain regions, there were no sig-
nificant correlations between the study effect sizes for gluta-
mate, glutamine, orGlx and themeanPANSS subscale scores,
chlorpromazine-equivalentdose, anddurationofpsychotic ill-
ness of patients with FEP or schizophrenia.
In all brain regions, therewas no association between the
meanageof thepatients and the effect size for glutamate, glu-
tamine, or Glx.
Small-Study Bias
Small-studybias,whichcould reflectpublicationbias,wasevi-
dent for reports ofGlx in themedial frontal region (Egger test,
P = .01) andGlx in the basal ganglia (P = .04). The year of pub-
lication was not significantly associated with metabolite re-
ports in any brain region.
Sensitivity Analysis
Leave-1-out sensitivity analysis showed that significant re-
sultswere generally robust. Significant differences didnot re-
main in 2 of 3 tests for cases of glutamine in the thalamus, in-
dicating an unreliable result.
Discussion
The number of publications reporting proton MRS measures
ofbrainglutamate,glutamine,orGlx inschizophreniahasmore
thandoubledsince the lastmeta-analysis.65 Inaddition toana-
lyzing data from a large number of new studies, wewere able
to include findings from brain regions precluded from previ-
ous meta-analysis in the present study.
We foundsignificantdifferences inglutamatergicmetabo-
lites across several cortical and subcortical regions in cases
compared with controls. Although the nature of the findings
varied depending on the patient subgroup and brain region,
all of the significant findings reflected elevations in glutama-
tergic metabolites in patients and HR individuals. This find-
ing is consistentwithdata fromanimalmodels of schizophre-
nia thatproposean increase inglutamatergic activity resulting
from NMDAR hypofunction.66 The finding is also consistent
with human studies of NMDAR hypofunction that show in-
creases inbothglutamateandglutamineconcentrations in the
cortex following ketamine administration to healthy volun-
teers.
TheHR, FEP, and schizophrenia groups had higher gluta-
mate andGlx levels in the basal ganglia, higher glutamine lev-
els in the thalamus, and higher Glx levels in theMTL. In con-
trast, thereweregenerallynosignificant findings in theDLPFC
or cerebellum, and significant findings in the medial frontal
cortex and frontal white matter were observed only in spe-
cific patient subgroups. Preclinical models propose that glu-
tamatergic overactivity in hippocampal areas drive excessive
subcortical dopamine release via polysynaptic glutamatergic
projections to the striatum. Likewise, abnormalities in stria-
tal glutamate may influence striatal dopaminergic signaling
since glutamate in the basal ganglia modulates tonic dopa-
mine release presynaptically via NMDARs. Finally, the thala-
mus receives efferent input from the striatum,78 andNMDAR
antagonism in the thalamus causes cortical neurotoxic injury
via corticothalamic loops.
In all regions except the basal ganglia, the HR, FEP, and
schizophrenia groups had significant elevations in the Glx or
glutamine signal rather than the glutamate signal,whichmay
partially reflect thegreaternumberof studies reportingonGlx
rather than glutamate or glutamine separately. Although the
glutamate signal accounts formost (80%-90%) of theGlx sig-
nal at field strengths of 1.5 T to 3T,6 it is possible thatGlx level
elevationscouldbedrivenby increases inglutaminerather than
glutamate levels. Following neurotransmission, glutamate is
converted to glutamine in astrocytes for recycling. Eleva-
tions in glutamine levels may thus reflect increases in gluta-
matergic synaptic activity. The previous meta-analysis27 re-
ported reduced medial frontal glutamate but elevated
glutamine levels in schizophrenia thatwerenotdetected in the
presentanalysis.Thisdiscrepancymayreflect improvedmeth-
ods in more recent studies since more studies acquired data
at higher field strengths, correct for voxel cerebrospinal fluid,
and specify more conservative thresholds for the acceptabil-
ity of metabolite fitting (eTable 3 in the Supplement).
Therewas some evidence that the regional degree of glu-
tamatergic elevationmaybe sensitive to illness stage. TheGlx
level elevations in themedial frontal cortex were apparent in
HR individuals but not in those with schizophrenia. Simi-
larly, medial frontal glutamine levels were elevated in 2
studies9,76 of patients with FEP, but no differenceswere seen
inpatientswithschizophrenia.Conversely,MTLGlx levelswere
elevated in individualswith schizophrenia but not in the FEP
or HR groups. One interpretation of these findings is that the
regional patternof glutamatergic abnormalities progresswith
the clinical course of the disorder or show differential re-
sponses to antipsychotic treatment.Most HR individuals will
not develop psychosis and were not receiving antipsychotic
medication; exclusionof this groupgenerally resulted in simi-
lar effect sizes. This observation suggests that inclusion of
HR groups did not dilute the findings in patients and that the
same pattern of glutamatergic-level elevation is apparent in
individuals atHRforpsychosis.Fewstudieshavedirectly com-
pared different patient groups23,24,57-59 or repeatedly as-
sessed glutamatergic metabolites over long periods.79 Inter-
pretation was limited because there were insufficient data to
analyzeall glutamatergicmeasures foreachpatientgroupsepa-
rately in every region.
Themeta-regression did not find support for the hypoth-
esis that glutamatergic metabolite concentrations in patients
vary inassociationwithage, antipsychotic treatment,or symp-
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tom severity. The latter may be relevant to the interpretation
of cross-sectional studies comparing regional glutamatergic
measures in association with antipsychotic treatment
response8 because this finding suggests that suchdifferences
may not simply involve group differences in symptom sever-
ity.Detailed informationonantipsychotic treatmentwasavail-
able in few data sets, and mean chlorpromazine-equivalent
doses may not account for medication adherence and do not
discriminate between the effects of different antipsychotic
medications. Longitudinal MRS studies have not found ef-
fects of antipsychotic treatment on medial frontal glutama-
tergicmeasures,76,79 althoughmedication effects in the stria-
tum have been reported.17 One previous study20 reported
higher medial frontal Glx in patients not receiving vs receiv-
ingmedications. Themeta-analysis foundhighermedial fron-
tal glutamine (butnot glutamateorGlx) levels inpatientswith
FEP, all of whomwere not receiving medications.
One limitation of the presentmeta-analysis is that, when
clinical groupswere analyzed separately, thenumber of stud-
ies per group for some regions was small. We conducted the
meta-analysiswhenat least3 independentdatasetswereavail-
able; however, findings based on a low number of data sets
shouldbe consideredpreliminary andarepresented to stimu-
late further research. Increases inGlx levels in themedial fron-
tal cortex inHR individuals and increases inMTLGlx levels in
patients with schizophrenia were reported by relatively large
numbers of studies; thus, these investigations represent the
most robust of the findings in patient subgroups.
Our HR category included studies of people at increased
familial risk for schizophrenia as well as those showing sub-
clinical signs of psychosis since there were too few studies to
permit separatemeta-analyses of each group. The risk of psy-
chosis differs between these groups, and this heterogeneity
mayexplainwhywedidnot findelevatedGlx levels in thebasal
ganglia and lower glutamate levels in the thalamus that have
been reported52 in clinical HR individuals. In addition, gluta-
mate may be increased only in HR persons who will later de-
velop psychosis or show poorer outcomes.52
Theresonance frequenciesofglutamateandglutaminesig-
nificantly overlap at 1.5 T, whereas glutamate can be largely
resolved at 3 T, and field strengths of 4 T or more are needed
tomeasureglutamineaccurately.6Forglutamine reports, a suf-
ficient number of studies were performed at 4 T only in the
thalamus.Given that glutaminemayprovideameasureof glu-
tamate turnover and our general finding of increased gluta-
mineorGlx rather thanglutamate inpatients, additional stud-
ies athigher field strengthsoptimized forglutamine resolution
should be a priority. Another limitation of this study is that
there was much variability in data acquisition and analysis
methods (eTable 3 in the Supplement), whichwill affect data
quality.Full reportingof such information in futurestudieswill
help to address sources of heterogeneity in subsequentmeta-
analyses.
Use of protonMRSprovides ameasure of total concentra-
tionswithin thevoxel studiedand thusdoesnot infer the func-
tional significanceof themetabolitesmeasured.However, glu-
tamine can act as an indirect measure of neurotransmitter
glutamate turnover since 80% of glutamine is used for gluta-
mate neurotransmitter cycling.7
Conclusions
Thismeta-analysis indicates that schizophrenia is associated
with glutamatergic-level elevations in several brain regions.
These findings further support the idea that pharmacologic
compounds that can reduce glutamatergic neurotransmis-
sion may have therapeutic potential.
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